FindTrial
Sign In

BLU-222

DRUG2 trials

Sponsors

Blueprint Medicines Corp., Blueprint Medicines Corporation

Conditions

Advanced Solid TumorsCCNE1 AmplificationCarcinosarcomaEndometrial CancerEsophageal AdenocarcinomaGastric CancerHER2-negative Breast CancerHR+ Breast Cancer

Phase 1

(VELA) Study of BLU-222 in Advanced Solid Tumors
TerminatedNCT05252416
Blueprint Medicines CorporationAdvanced Solid Tumors, Carcinosarcoma, CCNE1 Amplification +6
Start: 2022-04-07End: 2025-07-04Updated: 2025-11-28
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients with Advanced Solid Tumors
CompletedCTIS2022-502528-29-00
Blueprint Medicines Corp.HR+ Breast Cancer CCNE1 Amplification HER2-negative Breast Cancer Advanced Solid Tumor Ovarian Cancer Endometrial Cancer Gastric Cancer
Start: 2024-01-09End: 2025-07-04Target: 50Updated: 2025-06-25

Related Papers

Abstract 5330: Antitumor activity of potent and selective CDK2 inhibitors as monotherapy and in combination with chemotherapy in models of small cell lung cancer
Cancer Research2025-04-21
BLU-222, an investigational, oral, potent, and highly selective CDK2 inhibitor (CDK2i), as monotherapy in patients (pts) with advanced solid tumors and in combination with ribociclib (RIBO) and fulvestrant (FUL) in HR+/HER2− breast cancer (BC).
Journal of Clinical Oncology2024-06-0116 citations
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.
Journal of Clinical Oncology2023-06-0128 citations
Abstract P6-10-07: CDK2 inhibition with BLU-222 in combination with ribociclib demonstrates robust antitumor activity in pre-clinical models of CDK4/6 inhibitor-naïve and -resistant HR+/HER2- breast cancer
Cancer Research2023-03-019 citations
Abstract OT3-23-01: VELA: A first-in-human phase 1/2 study of BLU-222, a potent, selective cyclin-dependent kinase (CDK) 2 inhibitor in patients with cyclin E1 gene (CCNE1)-amplified or CDK4/6 inhibitor-resistant advanced solid tumors
Cancer Research2023-03-01